#ASCO22 Ironically, ENZAMET provides the best evidence yet that docetaxel layered on AR targeted therapy is still valuable for patients with the poorest prognosis (ie high volume, synchronous prostate cancer). OS benefit seen in the first 2-3 years only

#asco22 Key takeaways from VISION and ANZUP 1603:

1. Lu177-PSMA-617 more active than cabazitaxel, sequencing may not matter given OS results
2. PSMA PET SUV is an emerging biomarker, cutoff >10 most likely to benefit. Should prioritize these patients until drug shortages resolve

Looking forward to it @EBurgessMD. Folks, grab some take out and listen in for some interesting discussions and updates!

Thanks to Earle and the rest of the GU and pathology teams for their hard work getting this important paper published!